| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
-
May 24, 2012
Perrigo Company (Nasdaq: PRGO;TASE) today announced that Perrigo Chairman, President and Chief Executive Officer, Joseph C. Papa, will present at the...
-
May 22, 2012
Perrigo Company (Nasdaq: PRGO;TASE) today announced that it has received final approval from the U.S. Food and Drug Administration for its abbreviated...
-
May 18, 2012
Perrigo Company (Nasdaq: PRGO;TASE) today announced that it has received final approval from the U.S. Food and Drug Administration for its abbreviated...
-
May 15, 2012
Perrigo Company (Nasdaq: PRGO;TASE) today announced that Perrigo Executive Vice President and Chief Financial Officer, Judy L. Brown, will present at...
-
May 8, 2012-- Fiscal third quarter revenue from continuing operations increased $86 million, or 13%, to $778 million
Perrigo Company (Nasdaq: PRGO; TASE) today announced results for its third quarter ended March 31, 2012. (Logo:...
-
May 3, 2012
Perrigo Company (Nasdaq: PRGO;TASE) today announced that its Board of Directors declared a quarterly dividend of $0.08 per share, payable on June 19,...
-
Apr 24, 2012
Perrigo Company (Nasdaq: PRGO;TASE) today announced that it will release financial results for its third quarter fiscal 2012 on Tuesday, May 8, 2012...
-
Apr 12, 2012
Perrigo Company (Nasdaq: PRGO; TASE) announced that it has initiated shipments of its Guaifenesin Extended-Release Tablets, 600mg (a generic version...
-
Mar 21, 2012
Perrigo Company (Nasdaq: PRGO;TASE) today announced that it has received a final "Approval for Registration" letter from the Australian Therapeutic...
-
Mar 13, 2012
Perrigo Company (Nasdaq: PRGO;TASE) today announced that its Chairman, President and CEO Joseph C. Papa will present at the Barlcays Capital Global...